New plant in Taiwan to produce chemotherapy drugs
Construction on the new plant at the Central Taiwan Science Park’s Huwei Park due to begin this year
Taipei-based Orient Europharma Group (OEP) and Japan’s NanoCarrier Company have signed an agreement on a pancreatic cancer drug and unveiled their joint investment of US$24m in a new plant to produce cancer drugs. The two companies decided to continue their joint research on Nanoplatin, a Phase II chemotherapy drug, four years after they started developing it.
The new licence agreement will give the Taipei company non-exclusive manufacturing rights to the drug, also known as NC-6004, in addition to rights under the original licence agreement on the development and marketing of NC-6004 in the Asian countries.
In light of the new agreement, OEP said it would establish a new manufacturing subsidiary with NanoCarrier in Yunlin County to produce chemotherapy drugs given in injection form, with Nanoplatin being the first in line. Construction on the new plant at the Central Taiwan Science Park’s Huwei Park is to begin in 2013, and the facility is forecast to generate up to $500m in annual sales.
